Form 10-Q Neoleukin Therapeutics, For: Sep 30
FREE Breaking News Alerts from StreetInsider.com!
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Tech selloff weighs down Wall Street as bond yields climb
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Francisco Partners to acquire Weave Communications for $650M
Stifel Downgrades Neoleukin Therapeutics (NLTX) to Hold
November 15, 2022 4:58 AM ESTStifel analyst Benjamin Burnett downgraded Neoleukin Therapeutics (NASDAQ: NLTX) from Buy to Hold with a price target of $0.90 (from $14.00).
The analyst comments "We are downgrading shares to Hold following managements decision to discontinue development of lead asset NL-201 (next-gen IL-2 analogue). Management... More
